Efgartigimod therapy for immune checkpoint inhibitor–associated myasthenia gravis with myositis: a case report
Abstract The advent of immune checkpoint inhibitors (ICIs) has transformed cancer therapy, but their association with immune-related adverse events presents a new and complex challenge for clinicians. In this report, we present the case of a 60-year-old Han Chinese woman who developed myasthenia gra...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | BMC Neurology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12883-025-04288-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849238464340426752 |
|---|---|
| author | Feiteng Qi Qi Sun Haifeng Wang Yong Zhang |
| author_facet | Feiteng Qi Qi Sun Haifeng Wang Yong Zhang |
| author_sort | Feiteng Qi |
| collection | DOAJ |
| description | Abstract The advent of immune checkpoint inhibitors (ICIs) has transformed cancer therapy, but their association with immune-related adverse events presents a new and complex challenge for clinicians. In this report, we present the case of a 60-year-old Han Chinese woman who developed myasthenia gravis (MG) with myositis after pembrolizumab treatment for breast cancer. The patient presented with ptosis, slurred speech, limb weakness, and ocular fixation. Her creatine kinase level was elevated but she reported no muscle pain. The patient was diagnosed with ICI-associated MG with myositis. Before presenting to us, the patient had received low doses of intravenous methylprednisolone followed by oral prednisone, but her symptoms had continued to worsen. Her muscle strength improved significantly after we treated her with efgartigimod. This report is the first description of efgartigimod use in the treatment of ICI-associated MG with myositis, a new strategy for the treatment of this disease. |
| format | Article |
| id | doaj-art-7e6387ddaabe44c8aa62a52fb1a1c04f |
| institution | Kabale University |
| issn | 1471-2377 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Neurology |
| spelling | doaj-art-7e6387ddaabe44c8aa62a52fb1a1c04f2025-08-20T04:01:35ZengBMCBMC Neurology1471-23772025-07-012511410.1186/s12883-025-04288-0Efgartigimod therapy for immune checkpoint inhibitor–associated myasthenia gravis with myositis: a case reportFeiteng Qi0Qi Sun1Haifeng Wang2Yong Zhang3Department of Neurology, Ningbo Medical Center Lihuili HospitalDepartment of Neurology, Ningbo Medical Center Lihuili HospitalDepartment of Neurology, Ningbo Medical Center Lihuili HospitalDepartment of Neurology, The People’s Hospital of XinchangAbstract The advent of immune checkpoint inhibitors (ICIs) has transformed cancer therapy, but their association with immune-related adverse events presents a new and complex challenge for clinicians. In this report, we present the case of a 60-year-old Han Chinese woman who developed myasthenia gravis (MG) with myositis after pembrolizumab treatment for breast cancer. The patient presented with ptosis, slurred speech, limb weakness, and ocular fixation. Her creatine kinase level was elevated but she reported no muscle pain. The patient was diagnosed with ICI-associated MG with myositis. Before presenting to us, the patient had received low doses of intravenous methylprednisolone followed by oral prednisone, but her symptoms had continued to worsen. Her muscle strength improved significantly after we treated her with efgartigimod. This report is the first description of efgartigimod use in the treatment of ICI-associated MG with myositis, a new strategy for the treatment of this disease.https://doi.org/10.1186/s12883-025-04288-0EfgartigimodImmune checkpoint inhibitorMyasthenia GravisMyositis |
| spellingShingle | Feiteng Qi Qi Sun Haifeng Wang Yong Zhang Efgartigimod therapy for immune checkpoint inhibitor–associated myasthenia gravis with myositis: a case report BMC Neurology Efgartigimod Immune checkpoint inhibitor Myasthenia Gravis Myositis |
| title | Efgartigimod therapy for immune checkpoint inhibitor–associated myasthenia gravis with myositis: a case report |
| title_full | Efgartigimod therapy for immune checkpoint inhibitor–associated myasthenia gravis with myositis: a case report |
| title_fullStr | Efgartigimod therapy for immune checkpoint inhibitor–associated myasthenia gravis with myositis: a case report |
| title_full_unstemmed | Efgartigimod therapy for immune checkpoint inhibitor–associated myasthenia gravis with myositis: a case report |
| title_short | Efgartigimod therapy for immune checkpoint inhibitor–associated myasthenia gravis with myositis: a case report |
| title_sort | efgartigimod therapy for immune checkpoint inhibitor associated myasthenia gravis with myositis a case report |
| topic | Efgartigimod Immune checkpoint inhibitor Myasthenia Gravis Myositis |
| url | https://doi.org/10.1186/s12883-025-04288-0 |
| work_keys_str_mv | AT feitengqi efgartigimodtherapyforimmunecheckpointinhibitorassociatedmyastheniagraviswithmyositisacasereport AT qisun efgartigimodtherapyforimmunecheckpointinhibitorassociatedmyastheniagraviswithmyositisacasereport AT haifengwang efgartigimodtherapyforimmunecheckpointinhibitorassociatedmyastheniagraviswithmyositisacasereport AT yongzhang efgartigimodtherapyforimmunecheckpointinhibitorassociatedmyastheniagraviswithmyositisacasereport |